Sharekhan

Jagsonpal Pharmaceuticals Ltd

Mon 12/01/2026,13:49:11 NSE: JAGSNPHARM

₹ 178.41 -4.35 (-2.38%)
BUY NOW Buy Jagsonpal Pharmaceuticals Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Jagsonpal Pharmaceuticals Ltd

Mon 12/01/2026,13:52:0

Jagsonpal Pharmaceuticals Ltd

Mon 12/01/2026,13:49:11 | NSE : JAGSNPHARM

₹ 178.41-4.35 (-2.38%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 182.76

Previous Close

₹ 182.76

Volume

48750

Mkt Cap ( Rs. Cr)

₹1193.39

High

₹ 183.62

Low

₹ 176.11

52 Week High

₹ 301.65

52 Week Low

₹ 182.00

Book Value Per Share

₹ 37.81

Dividend Yield

1.35

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Jagsonpal Pharmaceuticals Ltd

Your Vote -

Buy

77.78%

Hold

11.11%

Sell

11.11%

77.78%

9 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

45%

Sell Order Quantity

55%

Bid Price

Qty

178.41

5

178.00

12

178.00

2

178.00

20

178.00

8

Bid Total

20554

Bid Price

Qty

178.69

6

179.00

12

179.00

6

179.00

21

179.00

19

Bid Total

25357

Option Chain

Analyzes market sentiment, predicts Jagsonpal Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Jagsonpal Pharma - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    6 Jan 2026, 5:16PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Jagsonpal Pharma - Updates

    6 Jan 2026, 5:04PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Allotment of 1,09,180 Equity Shares under the Jagsonpal Pharmaceuticals Limited

  • Jagsonpal Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    6 Jan 2026, 5:14PM Pursuant to Regulation 74(5) of SEBI (DP)Regulations, 2018 we are enclosing herewith a copy of the Certificate, received from MCS Share Transfer agent

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    6 Jan 2026, 5:02PM Allotment of 1,09,180 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022

  • Jagsonpal Pharma - Action(s) taken or orders passed

    30 Dec 2025, 4:53PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Action(s) taken or orders passed

  • Jagsonpal Pharma - Announcement Under Regulation 30 Of SEBI (LODR), 2015

    30 Dec 2025, 4:51PM Pursuant to provisions of Regulation 30 of SEBI (LODR), 2015, we hereby submit the disclosure regarding the order received from authority.

  • Jagsonpal Pharma - Trading Window

    26 Dec 2025, 12:55PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Reg

  • Jagsonpal Pharma - Copy of Newspaper Publication

    5 Dec 2025, 3:04PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

  • Jagsonpal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    20 Nov 2025, 8:53PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Schedule of meet

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    20 Nov 2025, 8:48PM Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that that the represe

  • Jagsonpal Pharma - Updates

    18 Nov 2025, 11:45AM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding allotment

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    18 Nov 2025, 11:39AM Allotment of 56,571 Equity Shares under the Jagsonpal Pharmaceuticals Limited employee stock option plan 2022.

  • Jagsonpal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    7 Nov 2025, 3:17PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Transcript

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    7 Nov 2025, 3:16PM Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, Please find enclosed transcript for the jagsonpal pharmaceuticals Limited Q2 FY 2026 earni

  • Jagsonpal Pharma - Copy of Newspaper Publication

    5 Nov 2025, 11:30AM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

  • Jagsonpal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Nov 2025, 5:12PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Link of Recording

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    4 Nov 2025, 5:10PM Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio

  • Jagsonpal Pharma - Press Release

    3 Nov 2025, 7:13PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 03, 2025, titled ""Press Release and Investor Pre

  • Jagsonpal Pharma - Investor Presentation

    3 Nov 2025, 7:10PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Investor Presentation

  • Jagsonpal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Nov 2025, 7:09PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Presentation

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    3 Nov 2025, 7:03PM Press Release and Investor Presentation on Un- Audited Financial Results for the quarter and half year ended September 30, 2025

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Investor Presentation

    3 Nov 2025, 7:00PM Press Release and Investor Presentation on Un- Audited Financial Results for the quarter and half year ended September 30, 2025

  • Jagsonpal Pharma Q2 net profit up 9.69% at Rs 12.57 cr

    3 Nov 2025, 5:40PM The company reported standalone net profit of Rs 12.57 crore for the quarter ended September 30, 2025 as compared to Rs 11.46 crore in the same period

  • Jagsonpal Pharma - Outcome of Board Meeting

    3 Nov 2025, 5:36PM Jagsonpal Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.

  • Jagsonpal Pharma - Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2025

    3 Nov 2025, 5:28PM Pursuant to regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015 Please find enclosed the Unaudited Financial results along with its Limited

  • Jagsonpal Pharma - Board Meeting Outcome for Outcome Of Board Meeting

    3 Nov 2025, 5:21PM Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we would like to inform you\r\nthat the Board of Directors at its Meeting

  • Jagsonpal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Oct 2025, 10:56AM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Schedule of meet

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    29 Oct 2025, 10:48AM Pursuant to Regulation 30 of SEBI (LODR) 2015, we wish to inform you that company has scheduled a conference call with analysts/Investor on 04, Novemb

  • Jagsonpal Pharma - Board Meeting Intimation for Intimation For Board Meeting.

    27 Oct 2025, 5:37PM Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2025 ,inter alia, to con

  • Jagsonpal Pharma has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2025

    17 Oct 2025, 3:30PM As of September 2025, 67.54% is owned by Promoters and 32.46% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 24.56% and
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Jagsonpal Pharmaceuticals Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 239.95 187.402 158.89 130.8556 128.717
Liabilities 239.95 187.402 158.89 130.8556 128.717
Equity 13.28 13.219 13.099 13.099 13.099
Gross Profit 51.071 23.067 34.151 25.7944 19.0785
Net Profit 55.361 22.463 26.721 19.587 17.0583
Cash From Operating Activities 55.3 35.166 46.655 5.5981 28.2224
NPM(%) 20.6 10.76 11.28 8.66 9.07
Revenue 268.716 208.702 236.714 226.0967 187.9456
Expenses 217.645 185.635 202.563 200.3023 168.8671
ROE(%) 21.89 8.88 10.56 7.74 6.74

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
12 Sep 2025 2.5 125 1.4 240.58
06 Sep 2024 5 100 1.4 351.15
21 Aug 2023 5 100 1.4 352.9
29 Oct 2021 4 80 1.4 162.15
22 Sep 2021 1 20 1.4 157.65
22 Sep 2020 0.5 10 1.4 35.15
20 Sep 2019 0.25 5 1.4 27.1
18 Sep 2018 0.1 2 1.4 26.7
21 Sep 2017 0.1 2 1.4 38.4
21 Sep 2016 0.1 2 1.4 33.85
21 Sep 2015 0.1 2 1.4 26.5
25 Sep 2014 0.5 10 1.4 23.65
25 Sep 2013 0.5 10 1.4 9.5
21 Sep 2012 0.5 10 1.4 12.35
23 Sep 2011 0.5 10 1.4 12.55
21 Sep 2010 0.5 10 1.4 23.85
23 Sep 2009 0.25 5 1.4 12.45
24 Sep 2008 0.1 2 1.4 13.4
21 Sep 2007 0.1 2 1.4 16.7
26 Sep 2006 0.1 2 1.4 19.25
26 Sep 2005 1 20 1.4 55.45
27 Aug 2004 0.5 10 1.4 244.25
30 May 2003 3.75 37.5 1.4 81.15
05 Mar 2002 0 20 1.4 111.85
11 Sep 2001 0 30 1.4 330
0 30 1.4 199

Peers

Other companies within the same industry or sector that are comparable to Jagsonpal Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 717.20 -1.90 0.00 104.96 301.39 0.70
Lotus Eye Hospital and Institute Ltd 110.61 -0.87 345.66 382.44 3.55 0.00
Vaishali Pharma Ltd 8.62 0.58 0.00 2399.20 3.13 0.00
Astec Lifesciences Ltd 630.85 -1.34 0.00 360.65 -604.77 0.00

Company Info

1995 - The Company is well poised to venture into new areas of activity which will propel it into achieving its projected goals. 1998 - The company is all set to realise it's laid-out expansion plans and gain substantially, both in sales volume and profits, with its proposed new product introductions, in the year. 1999 - The Company launched/re-launched a few products, which have been well received in the market. - The Company raised funds to the tune of Rs.5 crores through issue of 5,00,000 16% Non-Convertible Secured Debentures of Rs. 100 each to Life Insurance Corporation of India, General Insurance Corporation of India (GIC) and four subsidiaries of GIC. - The company is manufacturing off-patent drugs, where the entry barriers are relatively low. - The company has entered into tie-ups to make a range of anti-oxidants and hormones which are expected to be launched in 1999-2000. 2000 - The Company is having in-house share transfer and related facilities at the Registered office New Delhi. The Company is entering into an agreement with NSDL and CDSL for dematerialisation. 2004 -Company has issued a bonus shares in the ratio of 3:1. 2011 -The company has recommended a dividend of Rs. 0.50 per equity shares. 2013 -The company has recommended a dividend of Rs. 0.50 per equity shares. -Mr. Raj Kumar Kapoor has been appointed as Compliance officer cum Company Secretary of the company. 2014 -The company has recommended dividend of Rs. 0.50/- per Equity share. 2024 -The Company has informed regarding Acquisition for signing Business Transfer Agreement for the purchase of India & Bhutan business of Yash Pharma Laboratories Pvt.Ltd. -The Company Launches MemUp India's First Bioidentical Hormone Replacement Therapy in a Single Pill.

1995 - The Company is well poised to venture into new areas of activity which will propel it into achieving its projected goals. 1998 - The company is all set to realise it's laid-out expansion plans and gain substantially, both in sales volume and profits, with its proposed new product introductions, in the year. 1999 - The Company launched/re-launched a few products, which have been well received in the market. - The Company raised funds to the tune of Rs.5 crores through issue of 5,00,000 16% Non-Convertible Secured Debentures of Rs. 100 each to Life Insurance Corporation of India, General Insurance Corporation of India (GIC) and four subsidiaries of GIC. - The company is manufacturing off-patent drugs, where the entry barriers are relatively low. - The company has entered into tie-ups to make a range of anti-oxidants and hormones which are expected to be launched in 1999-2000. 2000 - The Company is having in-house share transfer and related facilities at the Registered office New Delhi. The Company is entering into an agreement with NSDL and CDSL for dematerialisation. 2004 -Company has issued a bonus shares in the ratio of 3:1. 2011 -The company has recommended a dividend of Rs. 0.50 per equity shares. 2013 -The company has recommended a dividend of Rs. 0.50 per equity shares. -Mr. Raj Kumar Kapoor has been appointed as Compliance officer cum Company Secretary of the company. 2014 -The company has recommended dividend of Rs. 0.50/- per Equity share. 2024 -The Company has informed regarding Acquisition for signing Business Transfer Agreement for the purchase of India & Bhutan business of Yash Pharma Laboratories Pvt.Ltd. -The Company Launches MemUp India's First Bioidentical Hormone Replacement Therapy in a Single Pill.

Read More

Parent Organisation

Jagsonpal Pharmaceuticals Ltd.

Founded

17/08/1978

Managing Director

Mr.Manish Gupta

NSE Symbol

JAGSNPHARMEQ

FAQ

The current price of Jagsonpal Pharmaceuticals Ltd is ₹ 178.41.

The 52-week high for Jagsonpal Pharmaceuticals Ltd is ₹ 183.62 and the 52-week low is ₹ 176.11.

The market capitalization of Jagsonpal Pharmaceuticals Ltd is currently ₹ 1193.39. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Jagsonpal Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Jagsonpal Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Jagsonpal Pharmaceuticals Ltd shares.

The CEO of Jagsonpal Pharmaceuticals Ltd is Mr.Manish Gupta, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT